drugset
Drugs / Lutetium Lu-177 PNT2002
last change Nov 2025 re-read 3 minutes ago

Lutetium Lu-177 PNT2002

Other / unclassified

Developed for
metastatic prostate carcinoma · prostate adenocarcinoma
Investigated by
Eli Lilly and Company · Jonsson Comprehensive Cancer Center

Trials 1

today NCT05496959 · Ph 2
2023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05496959 Sep 2022 → Sep 2032 expected metastatic prostate carcinoma, prostate adenocarcinoma Jonsson Comprehensive Cancer Center Active not recruiting Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Lutetium Lu-177 PNT2002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05496959 ↗
Modality Other / unclassified “prostate-specific membrane antigen (PSMA)-targeting radioligand therapy” PMID 41223345 ↗ Nov 2025
Route Intravenous “Patients receive 177Lu-PNT2002 intravenously (IV) over 1-10 minutes on days -112 and -56” NCT05496959 ↗